Synthego Receives Investment from Intel Capital

Synthego, a Redwood City, CA-based provider of genome engineering solutions, received an investment of undisclosed amount from Intel Capital.

The company intends to use the funds for the advancement of bioinformatics tools and technologies.

Led by Rich Stoner, PhD, Chief Science Officer, Synthego provides genome engineering solutions including software and synthetic RNA kits designed for CRISPR genome editing and research. Earlier this year, the company launched new CRISPR Workflow Software, consisting of a guide designer and design validator, to accelerate the guide RNA design process for CRISPR gene knockouts. It spans a dataset of over 113 billion targets across more than 123,000 genomes.
Customers include institutions in over 32 countries around the world, 8 of the world’s 10 largest biotechnology companies, and 24 of the top 25 global biology universities.



Join the discussion